Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2024 14:57 ET | Source: Research and Markets

Nivolumab Market Forecasts Indicate Robust Growth Driven by Advances in Cancer Immunotherapy and Increased Global Access to Care

Dublin, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The "Nivolumab Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Recent advancements in cancer treatment and the...
January 16, 2024 17:01 ET | Source: Adagene Inc.

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
December 14, 2023 10:08 ET | Source: Research and Markets

Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032

Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
April 13, 2021 08:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis

DELRAY BEACH, Fla., April 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
October 09, 2020 04:24 ET | Source: Research and Markets

Global Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast 20202030

Dublin, Oct. 09, 2020 (GLOBE NEWSWIRE) -- The "Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been...
June 02, 2020 08:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer

EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of ...
July 22, 2019 09:00 ET | Source: Therapeutic Solutions International, Inc.

Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer

OCEANSIDE, Calif., July 22, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc. (OTC Markets: TSOI) reported today positive animal data demonstrating synergy...